Terbinol cream

Form: Cream
Dosage: 1% - 10mg/g
Packaging: Tube 15g

Active substance :  terbinafine

Form : Semi-solid white cream for cutaneous application.

Dosage : 1 gram of cream contains 10 mg of terbinafine.

Packaging : 15 g tube

Target : Adults, adolescents and children (>12y)

Terbinol cream is used for the treatment of :

  • Fungal infections of the skin due to dermatophytes
  • Treatment of intertrigo of the toes (athlete’s foot) and genital and crural intertrigo.
  • Skin infections due to Candida
  • Pityriasis (tinea) versicolor (Malassezia furfur).

Irregular use or inadequate duration of treatment increases the risk of recurrence of symptoms.

The improvement of clinical symptoms usually appears within a few days. If there is no sign of improvement after 2 weeks, the diagnosis should be re-evaluated.

The skin must be cleaned and dried. The cream should be applied in a thin layer on and around the affected skin by gently penetrating it.

In case of eczematous and red infections (under the breast, between the fingers, between the buttocks or in the groin), the skin can be covered with a sterile compress after the application of the cream, especially at night.

Prescription drugs. Please contact your doctor.

Notice of Trademark Infringement

Dear valued partners, customers and Dafra representatives,

It has come to our attention that unauthorized use of our company’s name and logo has been observed in various contexts in the African country Togo (https://www.dafrapharma-vet.com/). In order to avoid misunderstandings, ever misleading, we feel it is imperative to address this issue promptly and transparently.

Trademark infringement poses a significant threat not only to our brand integrity but also to the trust and credibility we have worked diligently to establish within our community. Our name and logo represent our values, quality, and commitment to excellence, and any unauthorized use undermines these principles.

We take trademark infringement seriously and are actively taking measures to address any instances of unauthorized use. This includes legal action against parties found to be infringing upon our intellectual property rights.

We urge our customers, partners, African representatives and the general public to remain vigilant and report any suspected instances of trademark infringement directly to us. Your cooperation in this matter is crucial in helping us protect our brand and preserve the integrity of our business.

As always, we remain dedicated to providing high quality medical solutions in the sub-Sahara region of Africa and maintaining the highest standards of integrity and professionalism.

Thank you for your continued support and trust in our company.

Dafra Pharma